LC–MS for protein biomarkers: an interview with Ashley Phillips
In this interview, we spoke to Resolian’s Ashley Phillips about the work his team is doing on the LC–MS bioanalysis of proteins. Ashley discusses the suitability of LC–MS to analyze proteins and biomarkers using examples from his recent work.
Questions:
- What are the benefits of using LC–MS for the bioanalysis of proteins?
- What are the benefits of applying this approach to biomarkers?
- What are the drawbacks to this approach?
- Can you give an example of a protein biomarker you have measured by LC–MS and explain why protein LC–MS is suitable for this?
- These assays are difficult to develop. Did you encounter any challenges in your recent development?
Ashley Phillips
Senior Scientist, LC–MS Bioanalysis
Resolian (Fordham, UK)
Ashley Phillips is a Senior Scientist in Resolian’s LC–MS Bioanalysis division, where he oversees all team method development activities. These activities involve the development of robust LC–MS assays for the quantitation of therapeutics, biotherapeutics and biomarkers from biological matrices. He also mentors junior scientists on best practice and new techniques. Before joining Resolian, he attained his PhD under the supervision of Professor Perdita Barran at the University of Manchester (UK). His research focused on investigating the early-stage aggregates of amyloidogenic proteins using a range of techniques, including native mass spectrometry and ion mobility-mass spectrometry.
The opinions expressed in this interview are those of the interviewee and do not necessarily reflect the views of Bioanalysis Zone or Taylor & Francis Group.
In association with:
